Table 1.
Helicobacter pylori antimicrobial resistance trends between 2013 and 2020 in naïve patients.
| Resistance | Years—Number of Patients (%) | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | ||
| No resistance | 209 (49%) | 260 (50%) | 245 (49%) | 120 (44%) | 188 (55%) | 135 (48%) | 130 (48%) | 78 (36%) | 1365 (48%) |
| Clarithromycin | 85 (20%) | 119 (23%) | 136 (27%) | 91 (34%) | 83 (24%) | 76 (27%) | 76 (28%) | 35 (16%) | 701 (25%) |
| Metronidazole | 165 (39%) | 155 (30%) | 162 (32%) | 90 (33%) | 84 (25%) | 78 (28%) | 77 (29%) | 40 (18%) | 852 (30%) |
| Levofloxacin | 58 (14%) | 100 (19%) | 121 (24%) | 73 (27%) | 75 (22%) | 69 (25%) | 48 (18%) | 16 (7%) | 561 (20%) |
| Amoxicillin | 6 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (1.2%) | 1 (0.4%) | 0 (0%) | 0 (0%) | 11 (0,4%) |
| Tetracycline | 2 (0.5%) | 1 (0.2%) | 0 (0%) | 1 (0.4%) | 0 (0%) | 0 (0%) | 1 (0.4%) | 0 (0%) | 5 (0,2%) |
| Dual (C+M) | 56 (13%) | 64 (12%) | 77 (15%) | 45 (17%) | 41 (12%) | 34 (12%) | 35 (13%) | 16 (7%) | 368 (13%) |
| Triple (C+M+L) | 22 (5%) | 31 (6%) | 45 (9%) | 26 (10%) | 19 (5.5%) | 19 (6%) | 11 (4%) | 2 (0.9%) | 172 (6%) |
C—clarithromycin; M—metronidazole; L—levofloxacin.